Fundraising Fox
/Companies
Sign in

Felix Biotechnology

DefunctYC W20

San Francisco, US · Founded 2019 · 6 employees · 6 known investors

Find your way into Felix Biotechnology

Sign up to see every warm intro you have to Felix Biotechnology

  • Paths you didn't know you had: your email and LinkedIn already hold routes to the Felix Biotechnology team. We find them for you
  • 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
  • Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone

Days of research, done the moment you sign in, with every route ranked by how warm it is.

Sign up with GoogleAlready have an account? Log in

Felix Biotechnology develops a digital platform for designing viruses intended to combat antimicrobial resistance.

BiotechHealthtechGenomicsTherapeuticsUnited States of AmericaAmerica / CanadaPartly Remote

Founders & leadership· Y Combinator alumni (W20)

Felix Biotechnology was founded in 2019 by Robert McBride, Vivek Mutalik, and Paul Turner.

RMRobert McBride
Robert McBrideCo-Founder & CEO2019–2023Robert McBride founded Felix Biotechnology, which develops a digital platform for designing viruses to address antimicrobial resistance. He brings operations experience and has previously built and scaled ventures in science and technology sectors.
VMVivek Mutalik
Vivek MutalikCo-Founder2019–2023Vivek Mutalik is a staff scientist at Lawrence Berkeley National Laboratory and principal investigator at the U.S. Department of Energy's BRaVE Phage Foundry, where his research group develops technologies to engineer bacteria and bacteriophages for studying antibiotic resistance and microbiome applications.
PTPaul Turner
Paul TurnerFounder
NM
Natalie MaFounderuntil 2024
PTPaul Turner
Paul TurnerFounder

Investors · 6

First In Ventureslisted by First In VenturesMiddletown · $50K – $200K

How we know: the VCSheet dataset · Y Combinator's founder network · Not right? Tell us

Point72 Ventureslisted by Point72 VenturesNew York · $1M – $75M

How we know: funding news · the VCSheet dataset · open dataset · 5k.vc investor directory · Y Combinator's founder network · Not right? Tell us

Y Combinatorlisted by Y CombinatorSan Francisco · $500K

How we know: the Y Combinator directory · funding news · open dataset · 5k.vc investor directory · Not right? Tell us

Agrolimen Venturesreported

How we know: Y Combinator's founder network · Not right? Tell us

PioneerreportedToronto, Ontario

How we know: Y Combinator's founder network · Not right? Tell us

TalosVCreported

How we know: Y Combinator's founder network · Not right? Tell us

Related companies · 5

Sequence BioSequence Bio discovers genetic causes of disease within Newfoundland and Labrador's founder population to develop breakthrough treatments, diagnostics, and preventions. The company focuses on translational biology and genetics research for patients globally.
Ochre BioOchre Bio develops RNA therapeutics and drug discovery platforms targeting liver disease, combining proprietary human liver datasets with AI-driven causal prediction and human tissue validation models. The company aims to address the global shortage of liver transplants by developing new treatment options for liver fibrosis and cirrhosis.
Talus BioTalus develops a proprietary platform that measures and modulates the regulome—the body's gene expression control system—in native cellular contexts. The company designs AI-driven compounds and uses functional proteomics to enable drug discovery for transcription factors and regulatory proteins implicated in oncology, rare disease, and immune dysfunction.
CircumventCircumvent develops precision medicines for neurodegenerative diseases, with current focus on Batten Disease and other rare neurological disorders. The company's research targets synaptic dysfunction and lysosomal pathways through investigation of the palmitoylome.
GamgeeGAMGEE develops personalised mRNA cancer vaccines for dogs, created from the animal's own tumour tissue to help its immune system fight the cancer. The company manages the full process end to end—from diagnosis and tissue sampling with the pet owner's vet, to genomic analysis and treatment delivery via veterinary oncologists—and is currently running clinical trials in Australia while accepting applications globally.

Companies working in the same space as Felix Biotechnology.

Non-dilutive funding · 3 SBIR/STTR awards

Federal grants — no equity taken
AgencyPhaseYearAmount
National Institutes of Health (NIH)National Institutes of HealthPhase ISTTR2022$484.4K
National Institutes of Health (NIH)National Institutes of HealthPhase I2022$314.4K
National Science FoundationPhase I2021$256K

Source: SBIR.gov award data (U.S. Small Business Administration). SBIR/STTR awards are competitive federal R&D grants and contracts — non-dilutive capital alongside any venture rounds above.

Legal entities · 1

corporate structure
Felix Biotechnology, Inc.

In the news

Cystic Fibrosis Foundation Invests in Felix Biotechnology as They Advance New Therapies Targeting Chronic Infections in Cystic Fibrosis - BioSpacebiospace.com · Mar 2022Felix Biotechnology Awarded Competitive Grant from the National Science Foundation to Power Phage Engineering Platformprnewswire.com · Sep 2021Felix Biotechnology announces initiation of research collaboration with Biocogent, the leading provider of high technology products to personal care and cosmetic industries.prnewswire.com · Jun 2021

Frequently asked questions

What does Felix Biotechnology do?
Felix Biotechnology develops a digital platform for designing viruses intended to combat antimicrobial resistance.
Who founded Felix Biotechnology?
Felix Biotechnology was founded by Robert McBride, Vivek Mutalik, Paul Turner in 2019.
Who are Felix Biotechnology's investors?
Felix Biotechnology's investors include First In Ventures, Point72 Ventures, Y Combinator, Agrolimen Ventures, Pioneer, TalosVC.
Where is Felix Biotechnology headquartered?
Felix Biotechnology is headquartered in San Francisco, US.